eStudySite is proud to be on the front lines on the battle against drug resistant UTIs
Thanks to The New York Times for giving this resistance problem the front page attention it deserves! We're proud to be on the front lines on the battle against drug resistant UTIs. After reading this article please head over to our studies page for more info on current and upcoming UTI trials.
Rimegepant, a novel therapy for acute migraine, was featured in the New England Journal of Medicine. eStudySite is proud to have contributed
"For the first time in nearly three decades, people with migraine not helped by existing medications may have a new option to find relief during attacks," said Richard B. Lipton, M.D., the study's first author and Edwin S. Lowe Professor and vice chair of the Saul R. Korey Department of Neurology at Einstein and director of the Montefiore Headache Center.
eStudySite is honored to have contributed to this critical Gram-Positive antibiotic drug development
ECR among patients who received iclaprim and vancomycin at the ETP was 80.9% (241 of 298) of patients receiving iclaprim compared with 81.0% (243 of 300) of those receiving vancomycin (treatment difference, −0.13%; 95% confidence interval, −6.42%–6.17%). Iclaprim was well tolerated in the study, with most adverse events categorized as mild.
Sol-Gel Announces Positive Phase 2 clinical Trial Results for TWIN in Patients with Acne Vulgaris
As a longtime leader in dermatology clinical research, eStudySite is once again honored to have been given the opportunity to perform in another successful Acne trial. Our partner, Sol-Gel reports that TWIN Achieved Primary and Secondary Efficacy Endpoints with Statistical Significance and a Favorable Tolerability Profile.
Once again, eSS is the leading clinical site moving research against multidrug-resistance (MDR) infections
eStudySite’s is honored to have lead the way in this most important complicated intra-abdominal infections (cIAI) project and is pleased to share the positive topline results of IGNITE4, showing it's met its primary end point.
In April, Paratek Pharmaceuticals shared phase 3 data suggesting once-daily treatment with IV-to-oral omadacycline effectively and safely treats the most frequently isolated bacterial pathogens associated with skin infections, including methicillin-resistant Staphylococcus aureus (MRSA).
We are honored to have been lead author for the manuscript of our partner GSK’s novel first-in-class, triazaacenaphthylene antibacterial agent Gepotidacin and are excited about its potential.
NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the appointment of Dr. Thomas Lodise, Dr. Thomas Holland and Dr. William O’Riordan to the Clinical Advisory Board.
eSudySite is proud to have been instrumental in multiple Baxdela projects and publications over the last several years. It’s approval provides a much needed addition to the battle against ABSSSI and is another example of eStudySite as the world’s leading enroller in ABSSSI clinical trials.
Angiotensin II for the Treatment of Vasodilatory Shock
eStudySite’s is proud to be referenced in the May 25th print Issue of The New England Journal of Medicine for their contribution on “Angiotensin II for the Treatment of Vasodilatory Shock” out of our Las Vegas location.
Dr. Mike Waters Lecture on Nonalcoholic Fatty Liver Disease/NASH